Rezon Bio Appoints Dr. Ralf Otto as Chief Operating Officer to Support Next Phase of Growth and Operational Expansion
Rezon Bio, a science-driven European biologics contract development and manufacturing organization (CDMO), today announced the appointment of Dr. Ralf Otto, as Chief Operating Officer (COO) effective June 1, 2026. In his role, Ralf Otto, PhD, will be responsible for the operational areas of clinical and commercial cGMP manufacturing, development, quality, engineering and business operations across Rezon Bio’s integrated end-to-end CDMO platform.
FDA Approval Granted for Commercial Manufacturing at Rezon Bio's Warsaw-Duchnice Facility
Rezon Bio announces that its Warsaw-Duchnice facility has received approval from the U.S. Food and Drug Administration (FDA) for the commercial manufacturing of a biosimilar. This milestone represents an important step in the continued development of Rezon Bio’s global manufacturing network and reflects the company’s focus on building robust, compliant, and reliable capabilities to support biologic therapies for patients worldwide.
Rezon Bio Launches as a European Biologics CDMO Combining Cost Efficiency and Digital Innovation
Rezon Bio today announced its launch as a European contract development and manufacturing organization (CDMO) for biologics. It enters the market as a new brand, but builds on a proven legacy of advancing biologics from gene to global commercialization through established partners.
